Hot Features
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 fo... Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.93 | -7.09923664122 | 13.1 | 14.135 | 12.12 | 241364 | 12.83189069 | CS |
| 4 | -0.9 | -6.88599846978 | 13.07 | 14.135 | 12.12 | 198083 | 12.98866184 | CS |
| 12 | -2.53 | -17.2108843537 | 14.7 | 14.7999 | 11.95 | 392865 | 13.30135288 | CS |
| 26 | -59.37 | -82.9885378809 | 71.54 | 73.06 | 11.95 | 1371747 | 60.11531283 | CS |
| 52 | -22.22 | -64.6118057575 | 34.39 | 73.06 | 11.95 | 2645364 | 55.97524463 | CS |
| 156 | 0.97 | 8.66071428571 | 11.2 | 73.06 | 4.825 | 1719750 | 41.58915481 | CS |
| 260 | -9.75 | -44.4799270073 | 21.92 | 73.06 | 4.825 | 1301006 | 36.61292753 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.